Trial Search: "Kidney"



Treatment trials which apply specifically to your search:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-19-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-19-19

Trial Leaders:
Diana Hanna

The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 agonist) in Combination with INCAGN01949 (an activating anti-OX40 antibody) for In Situ Intratumoral Injection for Patients with Stage IV Pancreatic and other Cancers except Melanoma

Treatment:
Immunotherapy
Vaccine

0C-19-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers

Treatment:
Immunotherapy

0C-19-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

Treatment:
Biological Response Modifier

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-14

Trial Leaders:
Jorge Nieva

Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) Phase II Platform trial

Treatment:
Immunotherapy

0C-20-19

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study Of Ba3011 Alone And In Combination with Nivolumab In Adult And Adolescent Patients 12 Years And Older with Advanced Solid Tumors

Treatment:
Other

0C-21-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Treatment:
Immunotherapy

0C-21-14

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-6

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers

Treatment:
Other

0C-21-7

Trial Leaders:
Jacob Thomas

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma

Treatment:
Autologous Bone Marrow Transplant

0S-20-8

Trial Leaders:
Gino In

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Treatment:
Other
Vaccine

CTSU-A031702

Trial Leaders:
Anishka D'Souza

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Treatment:
Chemotherapy: Systemic
Immunotherapy

CTSU-A071801

Trial Leaders:
Eric Chang

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Treatment:
Radiation: External

SWOG-S1609

Trial Leaders:
Heinz Josef Lenz

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Treatment:
Immunotherapy

SWOG-S1614

Trial Leaders:
Irene Kang

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

Treatment:
Other

SWOG-S1931

Trial Leaders:
Varsha Tulpule

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Treatment:
Chemotherapy: Systemic
Immunotherapy
Surgery

Phase I trials for all solid tumors:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-20

Trial Leaders:
Jacob Thomas

A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-19-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-19-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-12

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Treatment:
Chemotherapy: Systemic
Other

0C-19-19

Trial Leaders:
Diana Hanna

The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 agonist) in Combination with INCAGN01949 (an activating anti-OX40 antibody) for In Situ Intratumoral Injection for Patients with Stage IV Pancreatic and other Cancers except Melanoma

Treatment:
Immunotherapy
Vaccine

0C-19-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers

Treatment:
Immunotherapy

0C-19-21

Trial Leaders:
Diana Hanna

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

Treatment:
Biological Response Modifier

0C-19-6

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer

Treatment:
Immunotherapy

0C-19-8

Trial Leaders:
Heinz Josef Lenz

A multicentre, open-label, non-randomised first in human study of NG-641, a tumor-selective transgene expressing adenoviral vector, in patients with metastatic or advanced epithelial tumours (STAR)

Treatment:
Immunomodulator

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

Treatment:
Other

0C-20-12

Trial Leaders:
Anthony El-Khoueiry

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Treatment:
Other

0C-20-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

Treatment:
Other

0C-20-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

Treatment:
Other

0C-20-18

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Treatment:
Other

0C-20-19

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study Of Ba3011 Alone And In Combination with Nivolumab In Adult And Adolescent Patients 12 Years And Older with Advanced Solid Tumors

Treatment:
Other

0C-20-2

Trial Leaders:
Anthony El-Khoueiry

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-20-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/1b Study of SRF388 in Patients with Advanced Solid Tumors

Treatment:
Other

0C-20-23

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Treatment:
Other

0C-20-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-20-3

Trial Leaders:
Mitchell Gross

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-20-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab

Treatment:
Other

0C-20-8

Trial Leaders:
Heinz Josef Lenz

First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors

Treatment:
Other

0C-20-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer

Treatment:
Other

0C-21-1

Trial Leaders:
Anthony El-Khoueiry

An Open Label Phase 1a/b Study Of Mtl-Cebpa In Combination With A Pd-1 Inhibitor (Pembrolizumab) In Adult Patients With Advanced Solid Tumours (Timepoint)

Treatment:
Immunotherapy

0C-21-10

Trial Leaders:
Anthony El-Khoueiry

Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Treatment:
Chemotherapy: Systemic

0C-21-12

Trial Leaders:
Anthony El-Khoueiry

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Treatment:
Immunotherapy

0C-21-14

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-15

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP707 Administered Intravenously in Subjects with Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Treatment:
Chemotherapy: Systemic

0C-21-19

Trial Leaders:
Jacob Thomas

A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and / or NRAS Mutation Positive Solid Tumors

Treatment:
Other

0C-21-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-4

Trial Leaders:
Jacob Thomas

A Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Pf-07257876 in Patients With Advanced or Metastatic Tumors

Treatment:
Other

0C-21-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

Treatment:
Other

0C-21-6

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers

Treatment:
Other

0C-21-7

Trial Leaders:
Jacob Thomas

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma

Treatment:
Autologous Bone Marrow Transplant

0C-21-8

Trial Leaders:
Heinz Josef Lenz

PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)

Treatment:
Other

0C-21-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Treatment:
Other

TEST002

Trial Leaders:
Francisco Acosta

Test Protocol 002 Long Protocol Title112

Treatment:
Autologous Bone Marrow Transplant
Biological Response Modifier
Chemotherapy: Local
Genetic




Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-4

Trial Leaders:
Charite Ricker

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-15-12

Trial Leaders:
John Carpten

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-16

Trial Leaders:
Casey O'Connell

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-16-5

Trial Leaders:
Heinz Josef Lenz

Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository


0S-19-4

Trial Leaders:
Jacob Thomas

A Tissue Collection Study in Patients who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells


0S-20-10

Trial Leaders:
Kimberly  Miller

Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study


0S-21-5

Trial Leaders:
Jacob Thomas

Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV) Antigens and Human Leucocyte Antigen (HLA) sub-Types in Patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.